Hikma Pharmaceuticals

TICKER: HIK     EXCHANGE: LSE

Hikma conducts its business in countries with very diverse demographic, geographic, political and socio-economic profiles, healthcare structures and needs. They range from the young and fast-growing Middle East and North Africa (MENA) region to mature markets like the US and Europe. It operates three well-diversified divisions: branded generics (sold in the MENA region), injectables (MENA, US and Europe) and generics (US). 

LATEST REPORTS

 
Good for patients, good for shareholders
Published: Sep 06 2012

Hikma conducts its business in countries with very diverse demographic, geographic, political and socio-economic profiles. It operates three well-diversified divisions: branded generics (sold in the MENA region), injectables (MENA, US and Europe) and generics (US). 
Further substantial growth shown at the half year stage: a 34.8% increase in net sales to US$532.3m and a 22% increase in net profits to US$40.4m. It appears that the Group is on track to deliver 20% growth in FY2012, as per management guidance.
Ongoing focus on R&D and their continuing flow of drug approvals / launches will to continue to support strong organic growth, giving further up-side potential to this share; the nature and scale of the next deal will influence growth rate and expectations

ARCHIVE